AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY OF WEEKLY INTRAVENOUS ALPHA1-PROTEINASE INHIBITOR (HUMAN), MODIFIED PROCESS 60 MG/KG IN SUBJECTS WITH PULMONARY EMPHYSEMA DUE TO ALPHA1-ANTITRYPSIN DEFICIENCY

Registry ID

GTI1201-OLE

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

GRIFOLS THERAPEUTICS INC

Start date

2020-09-23

Last update

2015-11-30

Conditions

• PULMONARY EMPHYSEMA

Related clinical trials

• "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWO DOSE REGIMENS (60MG/KG AND 120MG/KG) OF WEEKLY INTRAVENOUS ALPHA1-PROTEINASE INHIBITOR(HUMAN) IN SUBJECTS WITH PULMONARY EMPHYSEMA DUE TO ALPHA1-ANTITRYPSIN DEFICIENCY."

View on source registry